Results of the PRESTOCON preclinical trial are in
Results of the PRESTOCON preclinical trial are in
The results of the PRESTOCON preclinical trial have demonstrated that Panax ginseng and Gingko biloba extracts have a well-documented safety profile and are well tolerated for the treatment of moderate-to-severe disease.
In addition, the trial provided useful insights into the application of Panax ginseng (G115) and Gingko biloba (GK501) as novel and natural therapeutic intervention for the treatment of cognitive-related diseases.
These findings support the idea that the combination may become a valid and safe therapeutic intervention in the treatment of neurological disorders.
Robert Hendriks MD
Chief Executive Officer, SFI Health
Learn
Research is important, and we want to share it. Our articles distill the complex research and offer expert analysis on the microbiome, brain health and wellbeing.
Equazen® reaffirms its commitment to uncompromising quality and sustainability
Equazen® continues to set the benchmark for excellence at every step of the value chain.
Read more
Omega-3 and omega-6: the importance of balanced fatty acids
Omega-3 and omega-6 are both essential - but imbalance can fuel inflammation and chronic disease.
Read more
The 5 worst habits for your brain
Your brain is responsible for everything you do. It processes information, stores memories, and shapes who you are. Yet, many of us unknowingly engage in daily habits that can damage...
Read more